Mark Erlander, Cardiff Oncology CEO

Cardiff drops its prostate can­cer pro­gram, send­ing shares in­to a tail­spin

Cardiff On­col­o­gy is join­ing the league of com­pa­nies that have de­cid­ed to scrap one of its pro­gram, lead­ing the com­pa­ny’s stock to take a nose …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.